Guangzhou Lion TCR

Lion TCR is a clinical-stage biotechnology company specializing in the development of T-cell receptor (TCR) T-cell therapies for viral-related cancers and chronic infectious diseases. The company's primary focus is on Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), utilizing a proprietary platform to engineer T cells that target HBV antigens. Its lead candidate, LioCyx-M, is a first-in-class autologous TCR-T cell therapy that has demonstrated promising results in clinical trials for liver cancer. Headquartered in Singapore with major research and manufacturing facilities in Guangzhou, China, Lion TCR aims to provide precision immunotherapy solutions for patients with high unmet medical needs in the field of liver diseases.